Risk of Liver and Non-Liver Malignancy in HCV-Infected Patients with Cirrhosis After Direct-Acting Antiviral Treatment
Cancers · 26.06.2026 · 18 (13) · 2079
DOI: 10.3390/cancers18132079 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 26.06.2026. Verfasst von Dorota Zarębska-Michaluk und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases and Allergology, Collegium Medicum, Jan Kochanowski University, 25-516 Kielce, Poland. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jan Kochanowski University in Kielce, Poland.
Abstract (Originalsprache)
Background
Patients with liver cirrhosis remain at a persistent risk of developing hepatocellular carcinoma (HCC) and liver decompensation even after hepatitis C virus (HCV) eradication.
Objectives
We aimed to assess survival, the occurrence of recompensation and de novo decompensation events, and hepatic and extrahepatic malignancies in patients with liver cirrhosis during long-term observation (LTO) after direct-acting antiviral (DAA) treatment.
Methods
The study population consisted of 326 consecutive HCV-infected patients with liver cirrhosis treated with DAAs between 1 July 2015 and 30 June 2025 at a single tertiary hepatology center, of whom we followed 298 individuals for a median (IQR) of 4.4 (2.4–8.1) years after treatment completion.
Results
Men predominated in the study population, with a median age of 60 (48–69) years. The vast majority of patients had at least one comorbid condition. Fifty of them (16.8%) developed malignancies during LTO, including 33 cases of HCC and 17 with extrahepatic malignancies. New cases of HCC were documented as late as 9 years after DAA therapy. Overall, 103 patients (34.6%) died during LTO; 51 deaths occurred in patients with malignancies. Liver recompensation was observed in 27.8% of patients, while 9.9% experienced de novo decompensation events during LTO. The survival curve showed a gradual decline in survival probability from 0.96 at 1–2 years to 0.70 at 5 years and 0.51 at 10 years.
Conclusions
Patients with cirrhosis should remain under long-term hepatological monitoring after antiviral treatment, as they are still at risk of liver decompensation and the development of de novo HCC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Infectious Diseases and Allergology, Collegium Medicum, Jan Kochanowski University, 25-516 Kielce, Poland.
- Collegium Medicum, Jan Kochanowski University, 25-516 Kielce, Poland.
- Department of Infectious Diseases and Hepatology, Medical University of Bialystok, 15-540 Białystok, Poland.
- Department of Rheumatology and Connective Tissue Diseases, Nicolaus Copernicus Memorial Hospital, 93-513 Lodz, Poland.
- Department of Environmental Medicine, Poznan University of Medical Sciences, 60-806 Poznan, Poland.
- Department of Gastroenterology, Medical University of Lodz, 92-213 Lodz, Poland.
ORCID-Profile: Dorota Zarębska-Michaluk, Krystyna Dobrowolska, Robert Flisiak, Jakub Janczura, Piotr Rzymski, Michał Brzdęk
Förderung
- Jan Kochanowski University in Kielce, Poland
Zitieren
APA
Zarębska-Michaluk, D., Dobrowolska, K., Flisiak, R., Brzdęk, K., Janczura, J., Rzymski, P., & Brzdęk, M. (2026). Risk of Liver and Non-Liver Malignancy in HCV-Infected Patients with Cirrhosis After Direct-Acting Antiviral Treatment. Cancers, 18(13), 2079. https://doi.org/10.3390/cancers18132079
Vancouver
Zarębska-Michaluk D, Dobrowolska K, Flisiak R, Brzdęk K, Janczura J, Rzymski P, et al. Risk of Liver and Non-Liver Malignancy in HCV-Infected Patients with Cirrhosis After Direct-Acting Antiviral Treatment. Cancers. 2026;18(13):2079. doi:10.3390/cancers18132079
BibTeX
@article{ZarbskaMichaluk2026,
author = {Zarębska-Michaluk, Dorota and Dobrowolska, Krystyna and Flisiak, Robert and Brzdęk, Kinga and Janczura, Jakub and Rzymski, Piotr and Brzdęk, Michał},
title = {Risk of Liver and Non-Liver Malignancy in HCV-Infected Patients with Cirrhosis After Direct-Acting Antiviral Treatment},
journal = {Cancers},
year = {2026},
volume = {18},
number = {13},
pages = {2079},
doi = {10.3390/cancers18132079}
}
EUVIMED